Arcturus Therapeutics develops mRNA medicines for rare diseases and a COVID-19 vaccine, KOSTAIVE, with partner CSL Seqirus. It last closed at $7.97 on Nov 17, down 4.09% on the day. The average 12-month price target from 3 analysts is $19.67 (+146.8% from the last close), with a high of $20.00 and a low of $19.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Each firm's latest rating on ARCT in the past 90 days
Average 12-month target
$19.67
▲ 146.8% upside
Based on 3 analysts who set a price target on ARCT in the past 90 days. The average target is $19.67, with a high of $20.00 and a low of $19.00, compared with the last close of $7.97.
Low $19.00Avg $19.67High $20.00
Blue marker: last close $7.97
Highest target$20.00
Average target$19.67
Lowest target$19.00
Latest rating changes
Leerink PartnersMaintained
Oct 9Buy$19
CitigroupUpgrade
Sep 24Buy$20
BTIGMaintained
Sep 24Buy$20
Freedom BrokerInitiated
Jul 2Buy$27
Date
Firm
Action
Rating
Price target
Oct 9
Leerink Partners
Maintained
Buy
$19
Sep 24
Citigroup
Upgrade
Buy
$20
Sep 24
BTIG
Maintained
Buy
$20
Jul 2
Freedom Broker
Initiated
Buy
$27
Loading…
Technical Analysis
ARCT · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold
The stock is 25% below its 20 day and 52% below its 50 day average. It is 14% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $7.67, and the nearest resistance the Pivot at $7.99.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 13.2%/day
Key levels
$17.9652 week high+125.3%
$12.1350 day average+52.2%
$10.53100 day average+32.1%
$9.9520 day average+24.8%
$9.11200 day average+14.3%
$8.29Pivot R1+4.0%
$8.05Swing high (May 29)+1.0%
$7.99Pivot+0.3%
$7.97Last close
$7.67Pivot S1−3.8%
$6.71Swing low (Jun 11)−15.8%
$5.5052 week low−31.0%
Indicators
RSI (14)
35.24
Weak, oversold below 30
Neutral
MACD
-1.00
Below its signal line
Bearish
Stochastic
4.5
Near the bottom of its range
Oversold
ADX (14)
17.5
No clear trend
Williams %R
-94.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-158.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−16.5%
Change over 10 sessions
Bearish
ATR (14)
$1.05
Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityHigh, 28.4%/day
Key levels
$17.9652 week high+125.3%
$12.1350 day average+52.2%
$10.53100 day average+32.1%
$9.9520 day average+24.8%
$9.11200 day average+14.3%
$8.29Pivot R1+4.0%
$8.05Swing high (May 29)+1.0%
$7.99Pivot+0.3%
$7.97Last close
$7.67Pivot S1−3.8%
$6.71Swing low (Jun 11)−15.8%
$5.5052 week low−31.0%
Indicators
RSI (14)
42.42
Middle of its range
Neutral
MACD
0.22
Below its signal line
Bearish
Stochastic
17.9
Near the bottom of its range
Oversold
ADX (14)
25.4
Trending up
Williams %R
-97.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-50.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−45.9%
Change over 10 sessions
Bearish
ATR (14)
$2.27
Typical daily range, 28.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for ARCT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ARCT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ARCT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ARCT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARCT is in one of them and how their past ARCT trades turned out.
Arcturus Therapeutics is a messenger RNA medicines company based in San Diego, California. It develops treatments for rare genetic diseases, including candidates for ornithine transcarbamylase deficiency and cystic fibrosis. The company also develops vaccines, and its KOSTAIVE COVID-19 vaccine is partnered with CSL Seqirus and sold in Japan through Meiji Seika Pharma. Its proprietary LUNAR delivery system and STARR platform are used to build these medicines and vaccines.